Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.

被引：0
|
作者：
Chaft, Jamie E.
Costa, Daniel Botelho
Muzikansky, Alona
Shrager, Joseph B.
Lanuti, Michael
Huang, James
Ramchandran, Kavitha
Rangachari, Deepa
Huberman, Mark
Piotrowska, Zofia
Kris, Mark G.
Azzoli, Christopher G.
Sequist, Lecia V.
Neal, Joel W.
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Stanford Canc Inst, Stanford, CA USA
[6] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA
[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[8] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[9] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[10] Harvard Med Sch, Boston, MA 02115 USA
[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[12] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[13] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
[14] Stanford Univ, Stanford, CA 94305 USA
[15] Stanford Canc Inst, Stanford, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8507
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Real-world adjuvant treatment patterns in patients with stage I-III EGFR-mutated non-small cell lung cancer (NSCLC) in China: Interim analysis from the ADDRESS study
    Liang, W.
    Jiang, S.
    Chai, Y.
    Liu, W.
    Liu, L.
    Song, P.
    Wang, Z.
    Zhang, S.
    Xin, H.
    Liu, X.
    Xu, S.
    Zhang, H.
    Han, Y.
    Shen, W.
    Peng, Z.
    Geng, M.
    Yu, G.
    Zhang, X.
    He, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1062 - S1063
  • [42] A Randomized, Open Label, Phase II Study Comparing Pemetrexed plus Cisplatin versus Pemetrexed Alone in EGFR Mutant NSCLC after EGFR-TKI: QOL Data
    Yoo, Kwai Han
    Cho, Jinhyun
    Lee, Ki Hyeong
    Park, Keon Uk
    Kim, Ki Hwan
    Cho, Eun Kyung
    Kwon, Kyung A.
    Ahn, Heuijune
    Kim, Hye Ryun
    Kim, Hoon-Gu
    Lee, Ha Yeon
    Yun, Hwan Jung
    Kang, Jin Hyoung
    Jeong, Jaeheon
    Choi, Moon Young
    Jung, Sin-Ho
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1221 - S1222
  • [43] Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
    Luke, Jason J.
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Eggermont, Alexander M. M.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina V.
    Mohr, Peter
    Robert, Caroline
    Gershenwald, Jeffrey E.
    Poklepovic, Andrew Stewart
    Ross, Merrick I.
    Scolyer, Richard A.
    Yoon, Charles
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Sondak, Vernon K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [44] Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
    Takeshi Suto
    Megumi Ishiguro
    Chikuma Hamada
    Katsuyuki Kunieda
    Hiroyuki Masuko
    Ken Kondo
    Hideyuki Ishida
    Genichi Nishimura
    Kazuaki Sasaki
    Takayuki Morita
    Shoichi Hazama
    Koutarou Maeda
    Hideyuki Mishima
    Hideyuki Ike
    Sotaro Sadahiro
    Kenichi Sugihara
    Masazumi Okajima
    Shigetoyo Saji
    Junichi Sakamoto
    Naohiro Tomita
    International Journal of Clinical Oncology, 2017, 22 : 494 - 504
  • [45] Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
    Suto, Takeshi
    Ishiguro, Megumi
    Hamada, Chikuma
    Kunieda, Katsuyuki
    Masuko, Hiroyuki
    Kondo, Ken
    Ishida, Hideyuki
    Nishimura, Genichi
    Sasaki, Kazuaki
    Morita, Takayuki
    Hazama, Shoichi
    Maeda, Koutarou
    Mishima, Hideyuki
    Ike, Hideyuki
    Sadahiro, Sotaro
    Sugihara, Kenichi
    Okajima, Masazumi
    Saji, Shigetoyo
    Sakamoto, Junichi
    Tomita, Naohiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 494 - 504
  • [46] Adjuvant radiotherapy and concomitant raltitrexed in radically resected stage II-III rectal cancer. Definitive results of a phase I-II prospective study
    Bellavita, R
    Lupattelli, M
    Maranzano, E
    Trippa, F
    Mascioni, F
    Corgna, E
    Draghini, L
    Frattegiani, A
    Latini, P
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S170 - S170
  • [47] CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
    Wu, Yi-Long
    Zhong, Wenzhao
    Wang, Qun
    Mao, Weimin
    Xu, Song-Tao
    Wu, Lin
    Chen, Chun
    Cheng, Ying
    Xu, Lin
    Wang, Jun
    Li, Xiao-Fei
    Li, Jian
    Huang, Cheng
    Liu, Zhidong
    Xu, Shun
    Yang, Jin-Ji
    Yan, Hong-Hong
    Yang, Xue-Ning
    Liu, Si-yang
    Zhou, Qing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] A multicenter clinical randomized phase II study of investigating duration of adjuvant chemotherapy with S-1 (six versus 12 months) for patients with resected pancreatic cancer: PACS-1 study
    Yamashita, Yo-ichi
    Itoh, Shinji
    Shimokawa, Mototsugu
    Takamori, Hiroshi
    Fukuzawa, Kengo
    Ninomiya, Mizuki
    Araki, Kenichiro
    Kajiyama, Kiyoshi
    Sugimachi, Keishi
    Uchiyama, Hideaki
    Morine, Yuji
    Utsunomiya, Tohru
    Uwagawa, Tadashi
    Maeda, Takashi
    Adachi, Eisuke
    Ikeda, Yasuharu
    Yoshizumi, Tomoharu
    Baba, Hideo
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [49] Randomized phase II study of 6 versus 12 months of adjuvant imatinib for patients with intermediate- or high-risk GIST
    Muguruma, Kazuya
    Kurokawa, Yukinori
    Tsujinaka, Toshimasa
    Fujita, Junya
    Nakai, Takuya
    Takabayashi, Arimichi
    Hiramatsu, Masako
    Terashima, Masanori
    Iwasaki, Yoshiki
    Hasegawa, Junichi
    Kira, Toshihiko
    Shimokawa, Toshio
    Hirota, Seiichi
    Nishida, Toshirou
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [50] Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial
    Yoshino, Takayuki
    Oki, Eiji
    Misumi, Toshihiro
    Kotaka, Masahito
    Manaka, Dai
    Eto, Tetsuya
    Hasegawa, Junichi
    Takagane, Akinori
    Nakamura, Masato
    Kato, Takeshi
    Munemoto, Yoshinori
    Nakamura, Fumitaka
    Bando, Hiroyuki
    Taniguchi, Hiroki
    Sakamoto, Yasuhiro
    Shiozawa, Manabu
    Nishi, Masayasu
    Horiuchi, Tetsuya
    Yamagishi, Hisakazu
    Sakamoto, Junichi
    Mizushima, Tsunekazu
    Ohtsu, Atsushi
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) : 3419 - +
12345